This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

U.S. Requiring Controversial Vaccine

The Department of Homeland Security, against the recommendation of the Centers for Disease Control, is requiring girls and young women who immigrate to the U.S. to get a controversial vaccine for a cervical cancer virus.

Homeland Security's U.S. Citizenship and Immigration Services, or USCIS, is the first government agency to mandate that all females ages 11 to 26 years old be vaccinated against human papillomavirus, or HPV. There is no requirement for any other visa holders or U.S. citizens.

Since Homeland Security implemented the vaccination policy, the estimated 233,000 females ages 11 to 26 who entered the country as prospective citizens paid about a combined $52 million for one dose, based on the $223 cost for one treatment borne by the typical U.K. emigrant and average numbers taken from the Department of Homeland Security's "Yearbook of Immigration Statistics" over a four-year period.

Although one dose satisfies the Homeland Security vaccination protocol, three vaccinations, given over six months, are needed to be effective, according to Merck (MRK - Get Report), maker of the vaccine.

Jon Abramson, an infectious diseases expert and chairman of the CDC's Advisory Committee for Immunization Practices, or ACIP, when Homeland Security implemented the requirement in April 2007, advised against making the HPV vaccine mandatory at the time.

"I am stunned. It was not the intention of the policy to mandate vaccination of immigrants," Abramson said, adding that vaccination policies are designed to protect the populace, not individuals. "This is not a disease that is communicable like SARS or pandemic flu or even measles."
1 of 4

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
GSK $42.96 -0.92%
MRK $54.75 -1.80%
AAPL $93.50 -1.40%
FB $116.38 -0.30%
GOOG $693.13 0.31%


Chart of I:DJI
DOW 17,701.60 -129.16 -0.72%
S&P 500 2,059.78 -16.03 -0.77%
NASDAQ 4,765.0410 -40.25 -0.84%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs